ATE466592T1 - Anwendung von glp-2 in verbindung mit einem anderen therapeutischen mittel in knochenkrankheiten - Google Patents
Anwendung von glp-2 in verbindung mit einem anderen therapeutischen mittel in knochenkrankheitenInfo
- Publication number
- ATE466592T1 ATE466592T1 AT01967517T AT01967517T ATE466592T1 AT E466592 T1 ATE466592 T1 AT E466592T1 AT 01967517 T AT01967517 T AT 01967517T AT 01967517 T AT01967517 T AT 01967517T AT E466592 T1 ATE466592 T1 AT E466592T1
- Authority
- AT
- Austria
- Prior art keywords
- glp
- conjunction
- therapeutic agent
- another therapeutic
- bone diseases
- Prior art date
Links
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 2
- 208000020084 Bone disease Diseases 0.000 title 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 201000002980 Hyperparathyroidism Diseases 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0022844A GB0022844D0 (en) | 2000-09-18 | 2000-09-18 | Use of GLP-1 and GLP-2 peptides |
GB0029920A GB0029920D0 (en) | 2000-12-07 | 2000-12-07 | Use of glp-1 and glp-2 peptides |
PCT/GB2001/004178 WO2002024214A2 (en) | 2000-09-18 | 2001-09-18 | Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE466592T1 true ATE466592T1 (de) | 2010-05-15 |
Family
ID=26245018
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01982302T ATE396738T1 (de) | 2000-09-18 | 2001-09-17 | Verwendung von glp-2-peptiden |
AT01967517T ATE466592T1 (de) | 2000-09-18 | 2001-09-18 | Anwendung von glp-2 in verbindung mit einem anderen therapeutischen mittel in knochenkrankheiten |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01982302T ATE396738T1 (de) | 2000-09-18 | 2001-09-17 | Verwendung von glp-2-peptiden |
Country Status (11)
Country | Link |
---|---|
US (2) | US6770620B2 (de) |
EP (3) | EP1326630B1 (de) |
JP (2) | JP5161412B2 (de) |
AT (2) | ATE396738T1 (de) |
AU (2) | AU2002213925A1 (de) |
CY (2) | CY1108263T1 (de) |
DE (2) | DE60134251D1 (de) |
DK (2) | DK1326630T3 (de) |
ES (2) | ES2310192T3 (de) |
PT (2) | PT1326630E (de) |
WO (2) | WO2002022151A2 (de) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7186683B2 (en) * | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
EP1326630B1 (de) * | 2000-09-18 | 2008-05-28 | Sanos Bioscience A/S | Verwendung von glp-2-peptiden |
US20070135345A1 (en) * | 2000-09-18 | 2007-06-14 | Henriksen Dennis B | Use of GLP-2 for the treatment or prevention, of bone-related disorders |
US7371721B2 (en) * | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
RO120121B1 (ro) * | 2000-12-18 | 2005-09-30 | Elena Ionaşcu | Soluţie injectabilă, cu efect antiinflamator, procedeu de obţinere şi metodă de tratament a bolilor autoimune |
CA2372450A1 (en) * | 2001-05-10 | 2001-09-19 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
DE10135315A1 (de) * | 2001-07-19 | 2003-01-30 | Bayer Ag | Stents |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
US7109198B2 (en) * | 2002-05-17 | 2006-09-19 | Duke University | Method for treating obesity |
WO2004084859A2 (en) * | 2003-03-21 | 2004-10-07 | Nastech Pharmaceutical Company Inc. | Nasal calcitonin formulations containing chlorobutanol |
EP1608680A2 (de) * | 2003-03-24 | 2005-12-28 | Novo Nordisk A/S | Glp-2 derivate |
CA2522708C (en) | 2003-04-29 | 2013-05-28 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
EP1870096A3 (de) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Zusammensetzungen zur Beeinflussung von Gewichtsverlust |
CA2525574C (en) | 2003-05-15 | 2015-06-30 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
KR20060128995A (ko) * | 2004-01-13 | 2006-12-14 | 듀크 유니버시티 | 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물 |
WO2005110405A1 (en) * | 2004-05-03 | 2005-11-24 | Duke University | Compositions for affecting weight loss |
PL1877435T5 (pl) * | 2005-05-04 | 2021-09-27 | Zealand Pharma A/S | Analogi peptydu glukagonopodobnego 2 (GLP-2) |
WO2006135660A2 (en) * | 2005-06-10 | 2006-12-21 | University Of Chicago | Therapies involving lymphotoxin beta receptor |
CN101370488B (zh) | 2005-11-22 | 2012-07-18 | 奥雷西根治疗公司 | 增加胰岛素敏感性的组合物 |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
US20080031957A1 (en) * | 2006-05-15 | 2008-02-07 | Deluca Hector F | Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
WO2008056155A1 (en) | 2006-11-08 | 2008-05-15 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (glp-2) analogues |
JP2010508997A (ja) * | 2006-11-09 | 2010-03-25 | オレキシジェン・セラピューティクス・インコーポレーテッド | 減量薬を投与するための方法 |
TWI504419B (zh) | 2006-11-09 | 2015-10-21 | Orexigen Therapeutics Inc | 層狀醫藥調配物 |
US8940326B2 (en) | 2007-03-19 | 2015-01-27 | Vita Sciences Llc | Transdermal patch and method for delivery of vitamin B12 |
EP2187929A2 (de) * | 2007-09-11 | 2010-05-26 | Mondobiotech Laboratories AG | Verwendung eines peptids als therapeutisches mittel |
WO2009158114A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
EP2341942A1 (de) | 2008-09-19 | 2011-07-13 | Nektar Therapeutics | Polymerkonjugate aus therapeutischen peptiden |
US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
WO2011038014A2 (en) * | 2009-09-23 | 2011-03-31 | Biokier, Inc. | Composition and method for treatment of diabetes |
EP2311486A1 (de) * | 2009-10-07 | 2011-04-20 | Nestec S.A. | GLP-2 zur Verwendung in der Dünndarm- und Muskelwiederherstellung |
PL2498801T3 (pl) | 2009-11-13 | 2018-08-31 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę |
ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
RU2616496C2 (ru) | 2010-01-11 | 2017-04-17 | Ориксиджен Терапьютикс, Инк. | Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты) |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
HUE031181T2 (en) | 2010-08-30 | 2017-06-28 | Sanofi Aventis Deutschland | Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
EP2714089A4 (de) * | 2011-05-24 | 2014-11-26 | Polyvalor Sec | Zusammensetzungen und verfahren zur effizienten und sicheren abgabe von sirna mithilfe spezifischer chitosanbasierter nanokomplexe |
CN108079281A (zh) | 2011-08-29 | 2018-05-29 | 赛诺菲-安万特德国有限公司 | 用于2型糖尿病患者中的血糖控制的药物组合 |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
JP6298044B2 (ja) | 2012-05-03 | 2018-03-20 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン様ペプチド−2(glp−2)類似体 |
DK2858640T3 (da) | 2012-06-06 | 2020-06-29 | Nalpropion Pharmaceuticals Llc | Sammensætning til anvendelse i en fremgangsmåde til behandling af overvægt og fedme hos patienter med høj cardiovaskulær risiko |
MY181626A (en) | 2013-04-03 | 2020-12-29 | Sanofi Sa | Treatment of diabetes mellitus by long-acting formulations of insulins |
US10493042B2 (en) | 2013-08-01 | 2019-12-03 | University-Industry Cooperation Group Of Kyung Hee University | Method for preventing or treating diabetes mellitus, and method for screening for diabetes mellitus therapeutic agent |
WO2015016682A1 (ko) | 2013-08-01 | 2015-02-05 | 경희대학교 산학협력단 | 당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법 |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
US9950039B2 (en) | 2014-12-12 | 2018-04-24 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
US10631564B2 (en) | 2015-06-19 | 2020-04-28 | University Of Southern California | Enterically coated microparticle compositions and methods for modified nutrient delivery |
US10744070B2 (en) | 2015-06-19 | 2020-08-18 | University Of Southern California | Enteral fast access tract platform system |
WO2018009778A1 (en) * | 2016-07-07 | 2018-01-11 | Baylor College Of Medicine | Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes |
EP3526242A1 (de) | 2016-10-12 | 2019-08-21 | University of Copenhagen | Duale peptidagonisten von gipr und glp2r |
KR102502040B1 (ko) | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | 아실화 glp-1/glp-2 이중 효능제 |
EP3694537A1 (de) | 2017-10-12 | 2020-08-19 | University of Copenhagen | Kombinationstherapie zur behandlung von knochenerkrankungen |
US20210187077A1 (en) * | 2019-12-23 | 2021-06-24 | Idaho State University | GLP-1 Agonist Conjugates for Sustained Glycemic Control |
US20220362347A1 (en) * | 2019-12-24 | 2022-11-17 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating metabolic bone diseases, comprising glp-2 or conjugate thereof |
KR20220041765A (ko) * | 2020-09-25 | 2022-04-01 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1498425A1 (de) | 1986-05-05 | 2005-01-19 | The General Hospital Corporation | Verwendung von Glucagonähnlichem-Peptid-1 (GLP-1) Derivaten zur Herstellung von pharmazeutischen Zusammensetzungen |
JPH04504246A (ja) | 1989-03-20 | 1992-07-30 | ザ・ジェネラル・ホスピタル・コーポレーション | インシュリン刺激ホルモン |
WO1991011457A1 (en) | 1990-01-24 | 1991-08-08 | Buckley Douglas I | Glp-1 analogs useful for diabetes treatment |
NZ245015A (en) | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
US5512459A (en) | 1993-07-20 | 1996-04-30 | Bionebraska, Inc. | Enzymatic method for modification or recombinant polypeptides |
US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
US5789379A (en) | 1995-04-14 | 1998-08-04 | Allelix Biopharmaceutical Inc. | Glucagon-like peptide-2 analogs |
US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US5912229A (en) | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
DE69738695D1 (de) * | 1996-03-01 | 2008-06-26 | Novo Nordisk As | Peptid zur Appetitzügelung, dessen Zusammensetzungen und Verwendung |
AU733857B2 (en) | 1996-04-12 | 2001-05-31 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
JP3998717B2 (ja) | 1996-07-05 | 2007-10-31 | ノボ ノルディスク アクティーゼルスカブ | ポリペプチド類の製造方法 |
US5994500A (en) | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
JP2000517308A (ja) | 1996-08-30 | 2000-12-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―2誘導体 |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
CA2272854C (en) | 1996-12-06 | 2004-02-10 | Amgen Inc. | Keratinocyte growth factors and their use in combination with glucagon-like peptide derivatives |
US5952301A (en) | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
US6077949A (en) | 1996-12-13 | 2000-06-20 | Allelix Biopharmaceuticals, Inc. | Cloned glucagon-like peptide 2 receptors |
ATE358682T1 (de) | 1996-12-13 | 2007-04-15 | Allelix Biopharma | Klonierte rezeptoren des glukagon-ähnlichen peptids-2 |
BR9808804A (pt) | 1997-05-16 | 2001-09-18 | Ontario Inc | Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas |
US6051557A (en) | 1997-05-16 | 2000-04-18 | 1149336 Ontario Inc. | Methods of enhancing functioning of the upper gastrointestinal tract |
WO1999006059A2 (en) | 1997-07-30 | 1999-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions relating to no-mediated cytotoxicity |
JP2001516765A (ja) | 1997-09-12 | 2001-10-02 | ヴォルフ ゲオルグ フォースマン | 真性糖尿病及び肥満の治療のための組成物 |
EP1049790A1 (de) | 1998-01-23 | 2000-11-08 | Novo Nordisk A/S | Verfahren zur herstellung erwünschter polypeptide in hefe |
CA2819705C (en) | 1998-02-02 | 2014-07-08 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
AU2712899A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
FR2777283B1 (fr) * | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU7421598A (en) | 1998-05-11 | 1999-11-29 | 1149336 Ontario Inc. | Methods of enhancing functioning of the large intestine |
KR20010079669A (ko) | 1998-08-21 | 2001-08-22 | 바바라 피. 월너 | 기질 활성의 조절 |
US6193997B1 (en) | 1998-09-27 | 2001-02-27 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using membrane mimetics |
EP1119625B1 (de) | 1998-10-07 | 2005-06-29 | Medical College Of Georgia Research Institute, Inc. | Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon |
AU1525700A (en) * | 1998-11-19 | 2000-06-05 | Board Of Trustees Of The University Of Arkansas, The | Increasing bone strength with selected bisphosphonates |
US6903186B1 (en) * | 1998-12-07 | 2005-06-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S | Analogues of GLP-1 |
HUP0104579A3 (en) * | 1998-12-07 | 2002-05-28 | Univ Tulane | Glp-1 analogues, pharmaceutical compositions comprising thereof and their use |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6271200B1 (en) | 1998-12-21 | 2001-08-07 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles |
JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドglp−1アゴニスト |
GB9905416D0 (en) | 1999-03-09 | 1999-05-05 | Allelix Biopharma | Small molecules having GLP-2 like activity |
US6110949A (en) * | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
EP1076066A1 (de) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptide zur Senkung des Blutglukosespiegels |
US20030040478A1 (en) | 1999-12-08 | 2003-02-27 | Drucker Daniel J | Chemotherapy treatment |
WO2001087322A2 (en) * | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
HU229208B1 (en) * | 2000-06-16 | 2013-09-30 | Lilly Co Eli | Glucagon-like peptide-1 analogs |
BR0113178A (pt) * | 2000-08-02 | 2004-04-06 | Theratechnologies Inc | Peptìdeos biológicos modificados com potência aumentada |
EP1326630B1 (de) * | 2000-09-18 | 2008-05-28 | Sanos Bioscience A/S | Verwendung von glp-2-peptiden |
WO2002066062A2 (en) | 2001-02-01 | 2002-08-29 | Drucker Daniel J | Enhancement of glp-2 activity |
-
2001
- 2001-09-17 EP EP01982302A patent/EP1326630B1/de not_active Expired - Lifetime
- 2001-09-17 AT AT01982302T patent/ATE396738T1/de active
- 2001-09-17 EP EP08156283A patent/EP1970072A1/de not_active Withdrawn
- 2001-09-17 ES ES01982302T patent/ES2310192T3/es not_active Expired - Lifetime
- 2001-09-17 AU AU2002213925A patent/AU2002213925A1/en not_active Abandoned
- 2001-09-17 JP JP2002526401A patent/JP5161412B2/ja not_active Expired - Fee Related
- 2001-09-17 DK DK01982302T patent/DK1326630T3/da active
- 2001-09-17 WO PCT/EP2001/010714 patent/WO2002022151A2/en active IP Right Grant
- 2001-09-17 PT PT01982302T patent/PT1326630E/pt unknown
- 2001-09-17 US US09/954,304 patent/US6770620B2/en not_active Expired - Fee Related
- 2001-09-17 DE DE60134251T patent/DE60134251D1/de not_active Expired - Lifetime
- 2001-09-18 PT PT01967517T patent/PT1414486E/pt unknown
- 2001-09-18 ES ES01967517T patent/ES2345874T3/es not_active Expired - Lifetime
- 2001-09-18 AU AU2001287892A patent/AU2001287892A1/en not_active Abandoned
- 2001-09-18 DE DE60142084T patent/DE60142084D1/de not_active Expired - Lifetime
- 2001-09-18 WO PCT/GB2001/004178 patent/WO2002024214A2/en active Application Filing
- 2001-09-18 EP EP01967517A patent/EP1414486B1/de not_active Expired - Lifetime
- 2001-09-18 AT AT01967517T patent/ATE466592T1/de active
- 2001-09-18 DK DK01967517.2T patent/DK1414486T3/da active
- 2001-09-18 JP JP2002528284A patent/JP5189723B2/ja not_active Expired - Fee Related
-
2003
- 2003-03-18 US US10/391,460 patent/US6943151B2/en not_active Expired - Fee Related
-
2008
- 2008-08-13 CY CY20081100866T patent/CY1108263T1/el unknown
-
2010
- 2010-07-30 CY CY20101100721T patent/CY1110721T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1108263T1 (el) | 2014-02-12 |
WO2002024214A2 (en) | 2002-03-28 |
JP2004508410A (ja) | 2004-03-18 |
DK1414486T3 (da) | 2010-08-30 |
EP1414486A2 (de) | 2004-05-06 |
PT1326630E (pt) | 2008-09-02 |
EP1970072A1 (de) | 2008-09-17 |
AU2001287892A1 (en) | 2002-04-02 |
EP1326630A2 (de) | 2003-07-16 |
US20040082507A1 (en) | 2004-04-29 |
ATE396738T1 (de) | 2008-06-15 |
DK1326630T3 (da) | 2008-09-15 |
JP5189723B2 (ja) | 2013-04-24 |
AU2002213925A1 (en) | 2002-03-26 |
DE60134251D1 (de) | 2008-07-10 |
JP2004524268A (ja) | 2004-08-12 |
EP1414486B1 (de) | 2010-05-05 |
EP1326630B1 (de) | 2008-05-28 |
ES2310192T3 (es) | 2009-01-01 |
DE60142084D1 (de) | 2010-06-17 |
JP5161412B2 (ja) | 2013-03-13 |
CY1110721T1 (el) | 2015-06-10 |
ES2345874T3 (es) | 2010-10-05 |
US6770620B2 (en) | 2004-08-03 |
US6943151B2 (en) | 2005-09-13 |
PT1414486E (pt) | 2010-07-21 |
WO2002022151A3 (en) | 2003-03-13 |
WO2002022151A2 (en) | 2002-03-21 |
WO2002024214A3 (en) | 2004-02-19 |
US20020037836A1 (en) | 2002-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE466592T1 (de) | Anwendung von glp-2 in verbindung mit einem anderen therapeutischen mittel in knochenkrankheiten | |
UY27940A1 (es) | Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a | |
HRP20020593B1 (en) | Brain, spinal and nerve injury treatment | |
WO2004021968A3 (en) | Solution for ungual application | |
EE04852B1 (et) | C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel | |
ATE284172T1 (de) | Steuerbare schlaufenstrukturen zur unterstützung von diagnostischen und therapeutischen elementen in kontakt mit körpergewebe | |
DE69932510D1 (de) | Vaskularisierungsinhibitoren | |
AU2002339128A1 (en) | Use of reelin, gas6, and protein s in the treatment of neural disorders | |
BRPI0313792B8 (pt) | utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento | |
ES2167401T3 (es) | Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias. | |
ATE336491T1 (de) | Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung | |
PT1228028E (pt) | Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular | |
DE60142913D1 (de) | Arzneilösungen enthaltend modafinilverbindungen | |
GB2368525B (en) | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease | |
IT1305313B1 (it) | 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1. | |
HUP0400153A2 (en) | Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment | |
MY130445A (en) | Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone | |
DE50111407D1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
RS50681B (sr) | Kombinacija taksana i ciklin-zavisne kinaze | |
WO2002066492A3 (fr) | Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques. | |
IS6579A (is) | Tvenndarsameindir, sem innihalda peroxíðafleiður,framleiðsla og notkun þeirra við læknismeðferð | |
BR0209400A (pt) | Composição para cuidado de tecido, processo para o tratamento de tecido, e, uso de uma composição | |
Club et al. | Autism Spectrum Disorders | |
AR039883A1 (es) | Combinacion farmaceutica | |
RU2004118818A (ru) | Способ лечения больных с маточными кровотечениями |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1414486 Country of ref document: EP |